Cellebrite DI (CLBT)
Official siteTECHNOLOGY • SOFTWARE - INFRASTRUCTURE • NASDAQ
Market Cap: $2.90B
Last updated: Nov 17, 2026 at 11:05 AM ET
Cellebrite DI (CLBT) Financials: Revenue, Profit and Cash Flow
Cellebrite DI reported revenue of $475.68M for the fiscal year ended Dec 31, 2025, up 18.6% from the year before. That year, net income was $78.33M with a net margin of 16.5%, operating cash flow was $168.96M and free cash flow was $155.73M. The quarter ended Sep 30, 2026 had revenue of $149.02M and net income of $26.66M.
Revenue and Margins
The operating margin was 14.0% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $171.85M, a compound annual rate of 18.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $475.68M | +18.6% | 84.2% | 14.0% | 16.5% |
| Dec 2024 | $401.20M | +23.4% | 84.4% | 14.2% | -70.5% |
| Dec 2023 | $325.11M | +20.1% | 83.6% | 10.2% | -24.9% |
| Dec 2022 | $270.65M | +9.9% | 81.3% | 0.4% | 44.6% |
| Dec 2021 | $246.25M | +26.3% | 82.7% | 5.6% | 29.0% |
| Dec 2020 | $194.91M | +13.4% | 80.6% | 4.7% | 3.0% |
| Dec 2019 | $171.85M | N/A | 79.2% | -0.9% | -1.1% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 32.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $475.68M | $401.20M | $325.11M | $270.65M | $246.25M | $194.91M | $171.85M |
| Cost of revenue | $75.17M | $62.59M | $53.23M | $50.75M | $42.56M | $37.88M | $35.82M |
| Gross profit | $400.50M | $338.61M | $271.88M | $219.91M | $203.69M | $157.03M | $136.03M |
| Research and development | $113.88M | $98.42M | $84.39M | $80.62M | $65.54M | $54.38M | $46.57M |
| Operating income | $66.48M | $56.91M | $33.24M | $1.04M | $13.82M | $9.22M | -$1.52M |
| Net income | $78.33M | -$283.01M | -$81.10M | $120.81M | $71.40M | $5.78M | -$1.88M |
| EBITDA | $103.07M | N/A | N/A | $130.10M | $89.47M | $17.28M | $5.62M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $149.02M | $131.14M | $128.30M | $128.82M | $126.03M | $113.28M | $107.55M | $109.05M | $106.86M | $95.71M | $89.58M | $93.01M |
| Gross profit | $121.05M | $105.93M | $105.88M | $109.13M | $105.72M | $95.60M | $90.06M | $91.42M | $91.41M | $79.45M | $76.32M | $78.10M |
| Operating income | $26.88M | $7.63M | $9.12M | $20.80M | $18.99M | $14.42M | $12.27M | $15.73M | $19.45M | $12.49M | $9.25M | $15.00M |
| Net income | $26.66M | $6.37M | $10.94M | $21.26M | $20.19M | $19.48M | $17.40M | $19.27M | -$207.09M | -$23.81M | -$71.37M | -$14.65M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $4.00M by $120.46M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $938.85M | $690.57M | $532.88M | $403.29M | $339.78M | $364.39M | $280.24M |
| Current assets | $575.85M | $567.59M | $422.08M | $295.93M | $273.21M | $324.27M | $261.88M |
| Cash and equivalents | $124.46M | $191.66M | $189.52M | $87.64M | $145.97M | $128.71M | $76.55M |
| Total liabilities | $454.53M | $354.55M | $498.67M | $329.43M | $413.13M | $300.58M | $221.41M |
| Short-term debt | $4.00M | $4.13M | $4.97M | $5.00M | N/A | N/A | N/A |
| Shareholder equity | $484.32M | $336.02M | $34.21M | $73.86M | -$73.35M | $63.80M | $58.83M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.07B | $994.31M | $952.29M | $938.85M | $834.32M | $787.42M | $709.89M | $690.57M | $629.25M | $556.58M | $529.14M | $532.88M |
| Total liabilities | $489.18M | $456.21M | $441.75M | $454.53M | $386.63M | $379.01M | $346.40M | $354.55M | $330.93M | $596.74M | $555.84M | $498.67M |
| Cash and equivalents | $223.06M | $141.25M | $133.69M | $124.46M | $281.36M | $179.22M | $90.47M | $191.66M | $136.35M | $106.96M | $122.43M | $189.52M |
| Shareholder equity | $579.31M | $538.10M | $510.54M | $484.32M | $447.69M | $408.41M | $363.49M | $336.02M | $298.32M | -$40.16M | -$26.71M | $34.21M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 92.2% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $168.96M | $132.17M | $102.06M | $20.58M | $36.05M | $66.51M | $16.13M |
| Capital expenditures | $13.22M | $10.61M | $7.92M | $9.09M | $8.11M | $6.18M | $6.21M |
| Free cash flow | $155.73M | $121.56M | $94.14M | $11.49M | $27.94M | $60.33M | $9.92M |
| Dividends paid | N/A | N/A | $0 | $0 | $100.00M | $10.00M | $25.00M |
| Investing cash flow | -$268.25M | -$149.47M | -$22.54M | -$91.23M | $45.23M | -$6.45M | -$46.72M |
| Financing cash flow | $29.64M | $20.65M | $21.77M | $13.97M | -$68.40M | -$8.59M | $75.54M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $56.58M | $17.59M | $19.89M | $82.23M | $33.27M | $32.58M | $20.88M | $65.97M | $41.65M | $14.51M | $10.04M | $43.83M |
| Capital expenditures | $4.78M | $3.07M | $3.04M | $3.96M | $3.32M | $3.61M | $2.34M | $4.32M | $1.82M | $2.35M | $2.12M | $4.95M |
| Free cash flow | $51.80M | $14.52M | $16.84M | $78.27M | $29.95M | $28.98M | $18.54M | $61.65M | $39.83M | $12.16M | $7.92M | $38.88M |
Frequently Asked Questions About CLBT
What is Cellebrite DI's annual revenue?
Cellebrite DI reported revenue of $475.68M for the fiscal year ended Dec 31, 2025.
How fast is Cellebrite DI's revenue growing?
Revenue was up 18.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.7%.
Is Cellebrite DI profitable?
Yes. Cellebrite DI reported net income of $78.33M for the fiscal year ended Dec 31, 2025, with a net margin of 16.5%.
How much free cash flow does CLBT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $168.96M minus capital expenditures of $13.22M produced free cash flow of $155.73M.
How much debt does Cellebrite DI have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $4.00M and cash and equivalents of $124.46M.
CLBT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts